Attorney Docket No.: O 1999.475 US

In the Claims

1-10. (Cancelled)

Please amend the claims as follows:

11. (Presently Amended) A method for reversal of drug-induced neuromuscular block in a patient~~,~~ caused by a depolarizing or non-depolarizing neuromuscular blocking agent without causing an increase in the level of acetylcholine, comprising:
parentally administering to said ~~patent~~ patient an effective amount of a chemical chelator capable of forming a guest-host complex with the ~~drug~~ neuromuscular blocking agent inducing the neuromuscular block in ~~a~~ the patient.

12. (Presently amended) The method according to claim 11, wherein the ~~drug inducing the neuromuscular block in the patient~~ neuromuscular blocking agent is selected from the group consisting of rocuronium, vecuronium, pancuronium, rapacuronium, mivacuriam, (cis)atracuriam, tubocurarine or suxamethonium.

13. (Previously added) The method according to claim 11, wherein the chemical chelator is selected from the group

consisting of cyclic oligosaccarides and cyclophanes.

14. (Presently amended) The method according to claim 11, wherein the ~~drug inducing neuromuscular block in a patient~~ neuromuscular blocking agent is rocuronium and the chemical chelator is γ-cyclodextrin or a derivative thereof.

15. (Presently amended) A pharmaceutical composition, comprising:

a chemical chelator capable of reversing a drug-induced neuromuscular block, and ~~and~~ a pharmaceutically acceptable excipient.

16. (Previously added) The pharmaceutical composition according to claim 15, wherein the chelator is selected from the group consisting of cyclic oligosaccharides and cyclophanes.

17. (Previously added) The pharmaceutical composition according to claim 16, wherein the cyclic oligosaccharide is a cyclodextrin or a derivative thereof.

18. (Previously added) The pharmaceutical composition according to claim 17, wherein the cyclodextrin is γ-cyclodextrin or a derivative thereof.

Attorney Docket No.: O 1999.475 US

19. (Previously added) The pharmaceutical composition according to claim 16, wherein the cyclophane is represented by formula A



wherein R is



and n is 1-5; or

formula B



wherein X is



-4-

20. (New) The method according to claim 11, wherein the chemical chelator is γ-cyclodextrin or a derivative thereof.